Graham Samuel-Gibbon

Graham is Head of our Tax and Incentives team in the UK. He is an international tax specialist who advises domestic and multinational clients on a wide range of transactional and advisory tax matters. Graham regularly works with FTSE 100 and Future Global 100 companies.

He guides clients through stock and asset/business acquisitions and disposals, crossborder tax structuring, UK inbound and outbound investment, joint ventures and reorganisations.

He also advises on tax issues relating to the development, ownership and exploitation of intellectual property rights, with a particular focus on the life science and technology sectors.

CV

Since 2017 Partner, Taylor Wessing

2014 - 2017 Director, EY

2007 - 2014 Senior Associate, Latham & Watkins

Karriere

Since 2017 Partner, Taylor Wessing

2014 - 2017 Director, EY

2007 - 2014 Senior Associate, Latham & Watkins

Ausbildung

2001 Master's Degree, Jurisprudence II, University of Oxford, UK

2000 French Law, Université Panthéon Assas, Paris II, France

Fremdsprachen

Awards

ITR World Tax

Featured

Legal 500 UK 2023

Experience

Advising Chambers in £400 million sale to Abry Partners

We have advised the management team of Chambers and Partners on the sale of Inflexion's investment in the firm to Abry Partners, a leading middle market private equity firm headquartered in North America.

Press release

Emma Danks

Suzy Davis

Alexandra Poland

Kayla Sinclair

Graham Samuel-Gibbon

Claire Matthews

Sally Robertson

Elliot Michaelson Taylor

Siân Skelton

EQT on £1bn residential real estate joint venture.

Advised global investor EQT on a £1bn residential real estate joint venture, set to bring 3000 new rental homes to Greater London. The billion-sterling investment portfolio is being launched with residential property developer Sigma Capital. It is the first UK investment for EQT Real Estate, a division of global investor EQT Partners.

Press release

Edward Story

David Quinlan

Graham Samuel-Gibbon

Shilpa Vaswani

Ralph Wood

Glenmark Pharma on the sale of its portfolio of CNS products in Poland to Neuraxpharm

Advised Glenmark Pharma on its divestment of its CNS business in Poland including its portfolio of generics and branded generics products and the transfer of its commercial team in Poland to private equity backed Neuraxpharm, a specialty pharmaceutical company focused on the treatment of CNS disorders.

Press release

Emma Danks

Simon Jupp

Jason Rawkins

Graham Samuel-Gibbon

Babylon Health continues to invest in digital healthcare with largest European and US fundraising

Babylon Health, a UK-based digital health subscription provider, on its USD550m fundraising to support expansion into the US and Asia. This is the largest ever fundraising in the European or US digital health sector and values Babylon at over USD2bn. Investors included PIF, ERGO Fund, Kinnevik and Vostok New Ventures.

Press release

Josef Fuss

Graham Samuel-Gibbon

Beratung von Secret Escapes Übernahme von TravelBird und Pigsback.com

Beratung von Secret Escapes bei der Übernahme des niederländischen Unternehmens TravelBird, einem Online-Erlebnisunternehmen, und Pigsback.com, dem Marktführer in Irland für Hospitality-Angebote.

Press release

Richard Bursby

Tandeep Minhas

Louisa Penny

Graham Samuel-Gibbon

Sally Annereau

World's longest standing cryptocurrency exchange, Bitstamp, sells 80% stake to NXMH

We advised on the 80% sale of Bitstamp to Brussels-based investment firm, NXMH. Founded in the UK in 2011, Bitstamp is the world's longest standing cryptocurrency exchange and the EU's largest by volume, with more than three million registered customers.

Press release

Howard Palmer

Alexandra Richardson

Graham Samuel-Gibbon